Cargando…
Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review
The 22q11.2 deletion syndrome (22q11.2DS) is a multisystem condition and the most prevalent microdeletion syndrome in humans. Approximately 25% of individuals with 22q11.2DS receive antipsychotic treatment. To assess whether patients with 22q11.2DS are vulnerable to adverse effects of antipsychotic...
Autores principales: | de Boer, Janna, Boot, Erik, van Gils, Lissa, van Amelsvoort, Therese, Zinkstok, Janneke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851664/ https://www.ncbi.nlm.nih.gov/pubmed/31407842 http://dx.doi.org/10.1002/ajmg.a.61324 |
Ejemplares similares
-
Post-traumatic stress in adults with 22q11.2 deletion syndrome
por: von Scheibler, Emma N. M. M., et al.
Publicado: (2022) -
Adult Height, 22q11.2 Deletion Extent, and Short Stature in 22q11.2 Deletion Syndrome
por: Heung, Tracy, et al.
Publicado: (2022) -
22q11.2 Deletion Syndrome–Associated Parkinson's Disease
por: Boot, Erik, et al.
Publicado: (2018) -
Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study
por: Vingerhoets, Claudia, et al.
Publicado: (2020) -
Neurodevelopmental Trajectories and Psychiatric Morbidity: Lessons Learned From the 22q11.2 Deletion Syndrome
por: Fiksinski, Ania M., et al.
Publicado: (2021)